Pharma Mar S.A. Total Liabilities
Pharma Mar S.A. total liabilities. Based on the latest financial reports, Pharma Mar S.A. (PHM) has total liabilities worth €143.25 Million EUR (≈ $167.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pharma Mar S.A. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pharma Mar S.A. (2002–2025)
Total liabilities of Pharma Mar S.A. from 2002 to 2025. This chart illustrates how Pharma Mar S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore PHM long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Pharma Mar S.A. Competitors by Total Liabilities
The table below lists competitors of Pharma Mar S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nolato AB (publ)
ST:NOLA-B
|
Sweden | Skr4.36 Billion |
|
Shenzhen Qingyi Photomask Ltd
SHG:688138
|
China | CN¥1.12 Billion |
|
Teladoc Inc
NYSE:TDOC
|
USA | $1.49 Billion |
|
Cyient Limited
NSE:CYIENT
|
India | Rs21.61 Billion |
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
China | CN¥1.22 Billion |
|
China Resources Chemical Innovative Materials Co. Ltd.
SHE:301090
|
China | CN¥2.13 Billion |
|
Aryzta AG
SW:ARYN
|
Switzerland | CHF1.33 Billion |
|
Gs Retail
KO:007070
|
Korea | ₩4.51 Trillion |
Liability Composition Analysis (2002–2025)
This chart breaks down Pharma Mar S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PHM total asset value.
Liquidity & Leverage Metrics
Pharma Mar S.A. Total Liabilities Ratios Explained
Pharma Mar S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Mar S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Mar S.A. (2002–2025)
The table below shows the annual total liabilities of Pharma Mar S.A. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €143.25 Million ≈ $167.47 Million |
+1.39% |
| 2024-12-31 | €141.28 Million ≈ $165.18 Million |
-3.94% |
| 2023-12-31 | €147.08 Million ≈ $171.95 Million |
-13.63% |
| 2022-12-31 | €170.30 Million ≈ $199.10 Million |
-10.59% |
| 2021-12-31 | €190.47 Million ≈ $222.68 Million |
-16.29% |
| 2020-12-31 | €227.54 Million ≈ $266.01 Million |
+94.06% |
| 2019-12-31 | €117.25 Million ≈ $137.08 Million |
-16.37% |
| 2018-12-31 | €140.20 Million ≈ $163.91 Million |
-14.89% |
| 2017-12-31 | €164.74 Million ≈ $192.59 Million |
-4.58% |
| 2016-12-31 | €172.64 Million ≈ $201.84 Million |
+24.29% |
| 2015-12-31 | €138.90 Million ≈ $162.39 Million |
-1.71% |
| 2014-12-31 | €141.32 Million ≈ $165.22 Million |
+0.99% |
| 2013-12-31 | €139.94 Million ≈ $163.60 Million |
-13.14% |
| 2012-12-31 | €161.10 Million ≈ $188.35 Million |
-12.12% |
| 2011-12-31 | €183.31 Million ≈ $214.31 Million |
-6.45% |
| 2010-12-31 | €195.96 Million ≈ $229.10 Million |
+15.15% |
| 2009-12-31 | €170.18 Million ≈ $198.96 Million |
+7.57% |
| 2008-12-31 | €158.20 Million ≈ $184.95 Million |
+18.49% |
| 2007-12-31 | €133.51 Million ≈ $156.09 Million |
+13.89% |
| 2006-12-31 | €117.23 Million ≈ $137.06 Million |
+248.07% |
| 2005-12-31 | €33.68 Million ≈ $39.38 Million |
-6.72% |
| 2004-12-31 | €36.11 Million ≈ $42.21 Million |
-73.49% |
| 2003-12-31 | €136.20 Million ≈ $159.23 Million |
+30.29% |
| 2002-12-31 | €104.53 Million ≈ $122.21 Million |
-- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more